Rapid Medical Announces Ahead of Schedule Completion of Patient Enrollment for the TIGER Clinical Study for TIGERTRIEVER Thrombectomy Device
PR83590
YOKNEAM, Israel, April 08 /PRNewswire=KYODO JBN/ --
Rapid Medical [https://www.rapid-medical.com/], a company focused on the
development of next generation neurovascular interventional devices, has
announced that it has completed enrollment in the TIGER (Treatment with Intent
to Generate Reperfusion) study ahead of the planned scheduled. This is a US
based, multi-center study of the performance of TIGERTRIEVER, the company's
novel thrombectomy device for the acute treatment of ischemic stroke. The
TIGERTRIEVER is a fully-visible, controllable stentriever that is adjusted to
fit the dimensions of a blocked blood vessel causing acute ischemic stroke.
Vascular neurologist, Jeffrey Saver M.D., Stroke Neurology Director at
Ronald-Reagan-UCLA Medical Center in Los Angeles, California, and
neurointerventionalist Rishi Gupta M.D., Director, Neurocritical Care at
WellStar Health System, Georgia, are the principal investigators of the study.
“It was our honor and pleasure to co-lead this trial and we would like to thank
the patients, their families, and the clinical sites who participated in the
study. Their dedication enabled rapid patient recruitment and trial completion
ahead of schedule, despite the extra challenges of the current medical moment.”
said Prof. Saver.
"The TIGERTRIEVER is a new generation stentriever which provides the physician
with enhanced user control. Its unique design will hopefully show that it
addresses the limitations of current devices to provide optimal patient
outcomes. We are looking forward to publishing the data," stated Dr. Gupta.
TIGER is a multi-site, IDE study evaluating the safety and effectiveness of
Rapid’s TIGERTRIEVER for treatment of ischemic brain stroke. The study results
will be used as part of the 510K submission of the device for FDA clearance.
The study was completed ahead of schedule and took place at 16 of the leading
stroke centers throughout the U.S and one center in Israel. The TIGERTRIEVER
device has CE mark clearance and is commercially available in Europe; thousands
of ischemic stroke thrombectomy procedures are performed with the device every
year.
About Rapid Medical
Rapid Medical is developing game-changing devices for endovascular treatments.
Rapid Medical is the maker of TIGERTRIEVER and COMANECI, the first-ever
adjustable remodeling mesh. TIGERTRIEVER and COMANECI are CE marked for use in
Europe and COMANECI is also FDA approved. The TIGERTRIEVER is an
investigational device and is not available for sale in the United States.
More information is available at http://www.rapid-medical.com
Contact:
Eitan Havis,
VP of Sales and Marketing,
Rapid Medical
eitan@rapid-medical.com
+972-72-250-3331
Source: Rapid Medical
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。